Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

https://www.facingourrisk.org/XRAY/PARP-inhibitor-ovarian-cancer-survival

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Questions To Ask Your Health Care Provider

I have finished my first-line treatment. Should I consider maintenance therapy?
What are my options for maintenance therapy after chemotherapy?
What type of side effects should I expect on a PARP inhibitor?

Open Clinical Trials

The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.

NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. This studies how well adavosertib with or without olaparib work in patients with ovarian cancer that has come back (recurrent).

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.